Full text
Earnings transcript
Read the complete earnings call transcript.
CTMX
CytomX Therapeutics, Inc.
$4.56
0
(0%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 776.344M |
| Shares Outstanding: | 46.146M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Sean A. McCarthy | |||||
| Full Time Employees: | 119 | |||||
| Address: |
| |||||
| Website: | https://www.cytomx.com |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 101,214 | 138,103 | 76,201 |
| Gross Profit | 101,214 | 138,103 | 76,201 |
| EBITDA | -4,309 | 26,763 | -18,188 |
| Operating Income | -6,484 | 24,995 | -19,564 |
| Net Income | -569 | 31,869 | -17,368 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 201,792 | 120,533 | 151,566 |
| Total Liabilities | 249,239 | 120,989 | 52,558 |
| Total Stockholders Equity | -47,447 | -456 | 99,008 |
| Total Debt | 13,974 | 9,385 | 4,240 |
| Cash and Cash Equivalents | 17,171 | 38,052 | 12,667 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -56,035 | -86,231 | -75,587 |
| Capital Expenditure | -840 | -310 | -220 |
| Free Cash Flow | -56,875 | -86,541 | -75,807 |
| Net Income | -569 | 31,869 | -20,370 |
| Net Change in Cash | -176,479 | 20,991 | -24,885 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 51,047.202 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 589,777.508 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 196,943.250 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -246,228.282 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -21,311.875 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -82,222.528 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -1,239.028 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -12.744 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -344.839 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 28,184.267 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 325,628.950 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 108,736.638 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.010 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Product Pipeline: Based on the company profile and description, CTMX operates in the biotechnology industry, focusing on novel cancer therapies. This innovation-driven approach positions the company favorably within the high-growth healthcare sector.
- Strong Revenue Segments: Revenue product and geographic segment data indicate specific categories or regions contributing significantly to revenue, reflecting a diversified or focused income stream that supports financial stability.
- Positive Earnings Call Insights: Earnings call transcripts highlight management’s confidence in recent results, with key metrics such as revenue or EPS meeting or exceeding expectations, demonstrating operational competence.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CTMX valuation
Is CytomX Therapeutics, Inc. (CTMX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for CytomX Therapeutics, Inc. (CTMX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CTMX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CTMX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CTMX’s P/E ratio?
You can see CTMX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CTMX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CTMX a good long-term investment?
Whether CTMX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CTMX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
0
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 0.4 | Year High: | 8.21 | |
| Price Avg 50: | 5.21 | Price Avg 200: | 3.63 | |
| Volume: | 4.065M | Average Volume: | 6.862M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCTMX full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a really intriguing biotech stock, CytomX Therapeutics, ticker CTMX. If you’re into innovative cancer treatments and high-growth potential stocks, you’re gonna want to stick around for this comprehensive analysis. We’ll cover everything from their financials to their pipeline, recent performance, and whether this stock could be a buy for your portfolio. Let’s get started! First off, let’s set the stage. CytomX Therapeutics is a biopharmaceutical company focused on…
